Novartis Pharma Stein AG (manufacturing, quality control, primary and secondary packaging, batch release)
UkraineAll drugs from this manufacturer
-
The drug is prescribed for the treatment of periodic fever syndromes (CAP syndrome, TRAP syndrome, HID syndrome/MKD, familial Mediterranean fever), Still's disease (in adults and children), and for the symptomatic treatment of gouty arthritis attacks in adults.
Dosage form: powder for injection solution
Active substance Dosage canakinumab 150 mg ATC: L04AC08
-
The drug is used to treat adults with myelofibrosis (specifically with splenomegaly or disease symptoms), polycythemia vera (if other medicines are not suitable), and for the treatment of acute or chronic graft-versus-host disease in patients aged 12 years and older.
Dosage form: tablets
Active substance Dosage ruxolitinib 5 mg ATC: L01EJ01
-
The drug is used to treat adults with myelofibrosis (specifically with splenomegaly or disease symptoms), polycythemia vera (if other medicines are unsuitable), and for the treatment of acute or chronic graft-versus-host disease in patients aged 12 years and older.
Dosage form: tablets
Active substance Dosage ruxolitinib 15 mg ATC: L01EJ01
-
The drug is used to treat adults with myelofibrosis (particularly associated with splenomegaly), polycythemia vera (if other medicines are unsuitable), and for the treatment of acute or chronic graft-versus-host disease in patients aged 12 years and older.
Dosage form: tablets
Active substance Dosage ruxolitinib 20 mg ATC: L01EJ01